Treatment of advanced prostate cancer

250 mg every 8 hours; start 3 days before LHRH agonist

Molecular weight :276.2

%Protein binding :>90

%Excreted unchanged in urine : 45

Volume of distribution (L/kg) :No data

half-life – normal/ESRD (hrs) :6/Slightly increased (active metabolite)

20 to 50 : Dose as in normal renal function

10 to 20 : Dose as in normal renal function

<10 : Dose as in normal renal function

CAPD :Not dialysed. Dose as in normal renal function

HD :Not dialysed. Dose as in normal renal function

HDF/high flux :Not dialysed. Dose as in normal renal function

CAV/VVHD :Not dialysed. Dose as in normal renal function

Potentially hazardous interactions with other drugs

Anticoagulants: effects of coumarins enhanced

–

Oral

–